Following the U.S. approval, $45 million is due from AstraZeneca to Daiichi Sankyo Co., Ltd. DSKYF DSNKY as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) announced Tuesday they have withdrawn the EU marketing application for their experimental lung cancer therapy, datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. Provided by Dow Jones Jun 24, 2025, 6:33:00 AM By Adam Whittaker ...

AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan December 09, 2024 — 05:30 am EST Written by TheFly for TipRanks -> ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ...

AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast cancer drug Dato-DXd. Read more here.

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09 trial, when used as a ...

Daiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan.